

NCI Alliance for Nanotechnology in Cancer Status Report

Anna D. Barker, Ph.D. and Piotr Grodzinski, Ph.D.

Board of Scientific Advisors

June 23, 2008

NCI Approach: Alliance for Nanotechnology in Cancer

NCI Alliance for Nanotechnology in Cancer

Medical applications of nanotechnology require multi-disciplinary approach involving both technology developers and technology users in the process of innovation and product development

A comprehensive, systematized initiative encompassing the public and private sectors and designed to accelerate the use of the best capabilities of nanotechnology to cancer applications was launched by NCI in 2005

- Centers of Cancer Nanotechnology Excellence (CCNEs)
- Cancer Nanotechnology Platform Partnerships (CNPPs)
- Training programs
- Nanotechnology Characterization Laboratory (NCL)

Major Accomplishments

 Scientific standing – 475 journal papers published with average impact factor > 8.

 Clinical translation – over 30 companies formed and associated with the program in the space of diagnostics and therapy. Developing strong intellectual property portfolio - 133 disclosures and patents filed.

NCI Alliance for Nanotechnology

• Leveraged funding:

- over \$80 M of new, peer-reviewed government research funds (accumulative amount for period of next five years)
- over \$150 M of funds from philanthropic sources to establish infrastructure and perform research